A Systematic Framework for Drug Repositioning from Integrated Omics and Drug Phenotype Profiles Using Pathway-Drug Network

Drug repositioning offers new clinical indications for old drugs. Recently, many computational approaches have been developed to repurpose marketed drugs in human diseases by mining various of biological data including disease expression profiles, pathways, drug phenotype expression profiles, and chemical structure data. However, despite encouraging results, a comprehensive and efficient computational drug repositioning approach is needed that includes the high-level integration of available resources. In this study, we propose a systematic framework employing experimental genomic knowledge and pharmaceutical knowledge to reposition drugs for a specific disease. Specifically, we first obtain experimental genomic knowledge from disease gene expression profiles and pharmaceutical knowledge from drug phenotype expression profiles and construct a pathway-drug network representing a priori known associations between drugs and pathways. To discover promising candidates for drug repositioning, we initialize node labels for the pathway-drug network using identified disease pathways and known drugs associated with the phenotype of interest and perform network propagation in a semisupervised manner. To evaluate our method, we conducted some experiments to reposition 1309 drugs based on four different breast cancer datasets and verified the results of promising candidate drugs for breast cancer by a two-step validation procedure. Consequently, our experimental results showed that the proposed framework is quite useful approach to discover promising candidates for breast cancer treatment.

[1]  W. Han,et al.  ABCB1 polymorphism as prognostic factor in breast cancer patients treated with docetaxel and doxorubicin neoadjuvant chemotherapy , 2014, Cancer science.

[2]  Peer Bork,et al.  Drug-Induced Regulation of Target Expression , 2010, PLoS Comput. Biol..

[3]  Justin Lamb,et al.  The Connectivity Map: a new tool for biomedical research , 2007, Nature Reviews Cancer.

[4]  Diego di Bernardo,et al.  Drug-set enrichment analysis: a novel tool to investigate drug mode of action , 2015, Bioinform..

[5]  R. Plattner,et al.  STI571 sensitizes breast cancer cells to 5-fluorouracil, cisplatin and camptothecin in a cell type-specific manner. , 2009, Biochemical pharmacology.

[6]  Zhiyong Lu,et al.  A survey of current trends in computational drug repositioning , 2016, Briefings Bioinform..

[7]  Paul A Clemons,et al.  The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease , 2006, Science.

[8]  Manish Kumar Jeengar,et al.  Anticancer effect of celastrol on human triple negative breast cancer: possible involvement of oxidative stress, mitochondrial dysfunction, apoptosis and PI3K/Akt pathways. , 2015, Experimental and molecular pathology.

[9]  M. J. van de Vijver,et al.  Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. , 2006, Journal of the National Cancer Institute.

[10]  L. Sheffield.  C-Src activation by ErbB2 leads to attachment-independent growth of human breast epithelial cells. , 1998, Biochemical and biophysical research communications.

[11]  Zuping Zhang,et al.  Network-Based Inference Methods for Drug Repositioning , 2015, Comput. Math. Methods Medicine.

[12]  Christian von Mering,et al.  STITCH: interaction networks of chemicals and proteins , 2007, Nucleic Acids Res..

[13]  J. Foekens,et al.  Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer , 2005, The Lancet.

[14]  Jean Lu,et al.  Functional Module Connectivity Map (FMCM): A Framework for Searching Repurposed Drug Compounds for Systems Treatment of Cancer and an Application to Colorectal Adenocarcinoma , 2014, PloS one.

[15]  Alan F. Scott,et al.  Online Mendelian Inheritance in Man (OMIM), a knowledgebase of human genes and genetic disorders , 2002, Nucleic Acids Res..

[16]  Damian Szklarczyk,et al.  STITCH 4: integration of protein–chemical interactions with user data , 2013, Nucleic Acids Res..

[17]  Guanghui Hu,et al.  Human Disease-Drug Network Based on Genomic Expression Profiles , 2009, PloS one.

[18]  Rohaizak Muhammad,et al.  Gene expression patterns distinguish breast carcinomas from normal breast tissues: the Malaysian context. , 2010, Pathology, research and practice.

[19]  Evan Bolton,et al.  PubChem3D: conformer ensemble accuracy , 2013, Journal of Cheminformatics.

[20]  Liangfeng Han,et al.  Celastrol induces the apoptosis of breast cancer cells and inhibits their invasion via downregulation of MMP-9. , 2014, Oncology reports.

[21]  David S. Wishart,et al.  DrugBank 4.0: shedding new light on drug metabolism , 2013, Nucleic Acids Res..

[22]  Davide Heller,et al.  STRING v10: protein–protein interaction networks, integrated over the tree of life , 2014, Nucleic Acids Res..

[23]  Diego di Bernardo,et al.  Identifying Network of Drug Mode of Action by Gene Expression Profiling , 2009, J. Comput. Biol..

[24]  M. Wicha,et al.  CRLX101, an investigational camptothecin-containing nanoparticle-drug conjugate, targets cancer stem cells and impedes resistance to antiangiogenic therapy in mouse models of breast cancer , 2015, Breast Cancer Research and Treatment.

[25]  T. Ashburn,et al.  Drug repositioning: identifying and developing new uses for existing drugs , 2004, Nature Reviews Drug Discovery.

[26]  R. Tagliaferri,et al.  Discovery of drug mode of action and drug repositioning from transcriptional responses , 2010, Proceedings of the National Academy of Sciences.

[27]  Sanjay Joshua Swamidass,et al.  Mining small-molecule screens to repurpose drugs , 2011, Briefings Bioinform..

[28]  Douglas G Altman,et al.  Key Issues in Conducting a Meta-Analysis of Gene Expression Microarray Datasets , 2008, PLoS medicine.

[29]  Xin Wu,et al.  Drug repositioning by applying 'expression profiles' generated by integrating chemical structure similarity and gene semantic similarity. , 2014, Molecular bioSystems.

[30]  Y-Y Hsieh,et al.  Repositioning of a cyclin-dependent kinase inhibitor GW8510 as a ribonucleotide reductase M2 inhibitor to treat human colorectal cancer , 2016, Cell Death Discovery.

[31]  Yan Zhao,et al.  Drug repositioning: a machine-learning approach through data integration , 2013, Journal of Cheminformatics.

[32]  Tudor I. Oprea,et al.  Drug Repurposing: Far Beyond New Targets for Old Drugs , 2012, The AAPS Journal.

[33]  Jiyang Yu,et al.  Recovering Drug-Induced Apoptosis Subnetwork from Connectivity Map Data , 2015, BioMed research international.

[34]  Ian O. Ellis,et al.  Camptothecin targets WRN protein: mechanism and relevance in clinical breast cancer , 2016, Oncotarget.

[35]  R. Kurzrock,et al.  MS-275 Sensitizes TRAIL-Resistant Breast Cancer Cells, Inhibits Angiogenesis and Metastasis, and Reverses Epithelial-Mesenchymal Transition In vivo , 2010, Molecular Cancer Therapeutics.

[36]  P. Sebastiani,et al.  Gene expression in histologically normal epithelium from breast cancer patients and from cancer-free prophylactic mastectomy patients shares a similar profile , 2010, British Journal of Cancer.

[37]  S. Narayanan,et al.  Phosphodiesterase inhibitor, pentoxifylline enhances anticancer activity of histone deacetylase inhibitor, MS-275 in human breast cancer in vitro and in vivo. , 2015, European journal of pharmacology.

[38]  Y. Pommier,et al.  Acquired camptothecin resistance of human breast cancer MCF-7/C4 cells with normal topoisomerase I and elevated DNA repair. , 1996, Molecular pharmacology.

[39]  Robert L. Sutherland,et al.  Cyclin D as a therapeutic target in cancer , 2011, Nature Reviews Cancer.

[40]  Carsten Denkert,et al.  Differential expression of histone deacetylases HDAC1, 2 and 3 in human breast cancer - overexpression of HDAC2 and HDAC3 is associated with clinicopathological indicators of disease progression , 2013, BMC Cancer.

[41]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[42]  S. Shankar,et al.  HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinoma , 2005, Oncogene.

[43]  Yang Song,et al.  Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery , 2011, Nucleic Acids Res..

[44]  Alexander E. Ivliev,et al.  Drug Target Prediction and Repositioning Using an Integrated Network-Based Approach , 2013, PloS one.

[45]  Michael J. Keiser,et al.  Relating protein pharmacology by ligand chemistry , 2007, Nature Biotechnology.

[46]  Yoshihiro Yamanishi,et al.  KEGG for linking genomes to life and the environment , 2007, Nucleic Acids Res..

[47]  Roded Sharan,et al.  Large-Scale Elucidation of Drug Response Pathways in Humans , 2012, J. Comput. Biol..

[48]  J. Stenvang,et al.  Molecular characterization of irinotecan (SN-38) resistant human breast cancer cell lines , 2016, BMC Cancer.

[49]  Jui‐I Chao,et al.  Baicalein induces cancer cell death and proliferation retardation by the inhibition of CDC2 kinase and survivin associated with opposite role of p38 mitogen-activated protein kinase and AKT , 2007, Molecular Cancer Therapeutics.

[50]  J. Segall,et al.  ERBB1 and ERBB2 Have Distinct Functions in Tumor Cell Invasion and Intravasation , 2009, Clinical Cancer Research.

[51]  Elspeth A. Bruford,et al.  Genenames.org: the HGNC resources in 2015 , 2014, Nucleic Acids Res..

[52]  Alex E. Lash,et al.  Gene Expression Omnibus: NCBI gene expression and hybridization array data repository , 2002, Nucleic Acids Res..

[53]  Fan Zhang,et al.  Down-regulation of caspase 3 in breast cancer: a possible mechanism for chemoresistance , 2002, Oncogene.

[54]  Xin Wang,et al.  Identification of alsterpaullone as a novel small molecule inhibitor to target group 3 medulloblastoma , 2015, Oncotarget.

[55]  A. Barabasi,et al.  Drug—target network , 2007, Nature Biotechnology.

[56]  Samuel Kaski,et al.  Probabilistic drug connectivity mapping , 2014, BMC Bioinformatics.

[57]  Lincoln Stein,et al.  Reactome knowledgebase of human biological pathways and processes , 2008, Nucleic Acids Res..

[58]  Rafael A Irizarry,et al.  Exploration, normalization, and summaries of high density oligonucleotide array probe level data. , 2003, Biostatistics.

[59]  Helga Thorvaldsdóttir,et al.  Molecular signatures database (MSigDB) 3.0 , 2011, Bioinform..

[60]  P. Aloy,et al.  Unveiling the role of network and systems biology in drug discovery. , 2010, Trends in pharmacological sciences.